<DOC>
	<DOCNO>NCT00898560</DOCNO>
	<brief_summary>The purpose study investigate whether multiple-dose administration eslicarbazepine acetate ( ESL , BIA 2-093 ) 800 mg once-daily ( QD ) affect pharmacokinetics tolerability component combine oral contraceptive ( ethinyloestradiol levonorgestrel ) .</brief_summary>
	<brief_title>Effect Repeat Administration Eslicarbazepine Acetate Pharmacokinetics Combined Oral Contraceptive</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Premenopausal female subject Age 1840 year , inclusive Body mass index ( BMI ) 1930 kg/m2 , inclusive Healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG Negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screen Negative urine pregnancy test screen admission treatment period . Using one follow method contraception : double barrier intrauterine device Subjects contraindication use oral contraceptive History presence clinically relevant disease , disorder surgical history History alcoholism drug abuse Have use medicine within two week admission first period may affect safety study assessment , investigator 's opinion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Partial</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Eslicarbazepine acetate</keyword>
	<keyword>Combined oral contraceptive</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tolerability</keyword>
</DOC>